MARKET

QURE

QURE

Uniqure
NASDAQ
20.50
-1.87
-8.36%
After Hours: 20.68 +0.18 +0.88% 19:56 02/13 EST
OPEN
22.37
PREV CLOSE
22.37
HIGH
22.60
LOW
20.17
VOLUME
2.35M
TURNOVER
--
52 WEEK HIGH
71.50
52 WEEK LOW
7.76
MARKET CAP
1.28B
P/E (TTM)
-4.6748
1D
5D
1M
3M
1Y
5Y
1D
QURE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against uniQure N.V.
PR Newswire · 4h ago
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
PR Newswire · 20h ago
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
PR Newswire · 20h ago
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
PR Newswire · 1d ago
Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) - Contact Kessler Topaz Meltzer & Check, LLP
Barchart · 1d ago
Assessing uniQure (QURE) Valuation After New Securities Fraud Lawsuit On AMT-130 Disclosures
Simply Wall St · 2d ago
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
Barchart · 2d ago
INVESTOR ALERT: Securities Class Action Filed Against uniQURE N.V. – Investors Encouraged to Contact Kirby McInerney LLP
Barchart · 2d ago
More
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers Uniqure NV stock information, including NASDAQ: QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.